The BPALM regimen is a combination therapy used primarily for treating multidrug-resistant tuberculosis (MDR-TB). It includes the following drugs:
- Bedaquiline – a diarylquinoline that inhibits mycobacterial ATP synthase, killing Mycobacterium tuberculosis.
- Pretomanid – a nitroimidazole that inhibits mycolic acid synthesis and generates reactive nitrogen species.
- Linezolid – an oxazolidinone antibiotic inhibiting bacterial protein synthesis by binding to the 50S ribosomal subunit.
- Moxifloxacin – a fluoroquinolone antibiotic that inhibits DNA gyrase and topoisomerase IV, interfering with bacterial DNA replication.
This combination is preferred due to its efficacy and synergy against resistant strains. The inclusion of moxifloxacin is specific to option (c), making it the correct answer.